Stock listing
NASDAQ:ESLA Estrella Immunopharma, Inc. Stock
Home listing (NASDAQ) of Estrella Immunopharma, Inc.
Follow Estrella Immunopharma, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ESLA
$0.321 USD -0.012 (-3.6%)
Close on Nov 20, 2026
- Day range
- $0.321 – $0.400 USDNov 20, 2026
- Volume
- 251,677 sharesNov 20, 2026
- Market cap
- $14.11M USDAt the close on Nov 20, 2026 · price × 43.97M shares outstanding
- 52-week range
- $0.240 – $2.270 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.09M USDMedian day 71,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ESLA · Home | $0.321 USD | -0.012 (-3.6%) | 251,677 | $0.360 | $0.400 | $0.321 | $0.333 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ESLA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.321 | -0.012 | -3.6% | $0.360 | $0.400 | $0.321 | 251,677 | |
| $0.333 | +0.001 | +0.4% | $0.335 | $0.380 | $0.330 | 446,508 | |
| $0.332 | -0.048 | -12.7% | $0.440 | $0.470 | $0.300 | 747,761 | |
| $0.380 | -0.134 | -26.1% | $0.499 | $0.525 | $0.380 | 532,000 | |
| $0.514 | -0.005 | -1.0% | $0.521 | $0.552 | $0.464 | 222,000 | |
| $0.519 | -0.275 | -34.6% | $0.799 | $0.799 | $0.400 | 1,585,900 | |
| $0.794 | +0.047 | +6.3% | $0.775 | $0.851 | $0.731 | 782,800 | |
| $0.747 | +0.233 | +45.3% | $0.530 | $0.770 | $0.530 | 3,951,900 | |
| $0.514 | +0.139 | +37.1% | $0.430 | $0.599 | $0.430 | 6,584,500 | |
| $0.375 | -0.035 | -8.5% | $0.400 | $0.445 | $0.372 | 140,400 | |
| $0.410 | -0.034 | -7.7% | $0.444 | $0.444 | $0.400 | 162,800 | |
| $0.444 | +0.026 | +6.2% | $0.438 | $0.480 | $0.403 | 128,700 | |
| $0.418 | -0.008 | -1.9% | $0.429 | $0.475 | $0.352 | 526,300 | |
| $0.426 | -0.213 | -33.3% | $0.639 | $0.639 | $0.425 | 617,000 | |
| $0.639 | -0.090 | -12.3% | $0.720 | $0.787 | $0.624 | 165,700 | |
| $0.729 | -0.093 | -11.3% | $0.812 | $0.825 | $0.701 | 270,200 | |
| $0.822 | -0.110 | -11.8% | $0.918 | $0.990 | $0.751 | 495,600 | |
| $0.932 | +0.013 | +1.4% | $0.880 | $0.950 | $0.846 | 609,700 | |
| $0.919 | -0.066 | -6.7% | $1.050 | $1.150 | $0.880 | 2,579,400 | |
| $0.985 | +0.258 | +35.5% | $0.764 | $0.999 | $0.741 | 3,718,700 | |
| $0.727 | +0.177 | +32.2% | $0.562 | $0.759 | $0.555 | 6,851,000 | |
| $0.550 | +0.150 | +37.5% | $0.419 | $0.591 | $0.388 | 7,019,400 | |
| $0.400 | +0.020 | +5.3% | $0.349 | $0.419 | $0.334 | 193,900 | |
| $0.380 | -0.050 | -11.6% | $0.369 | $0.424 | $0.240 | 1,695,900 | |
| $0.430 | -0.105 | -19.6% | $0.495 | $0.510 | $0.421 | 4,239,600 | |
| $0.535 | +0.217 | +68.2% | $0.310 | $0.850 | $0.302 | 63,107,500 | |
| $0.318 | +0.004 | +1.3% | $0.310 | $0.330 | $0.300 | 198,900 | |
| $0.314 | -0.015 | -4.6% | $0.330 | $0.342 | $0.295 | 319,000 | |
| $0.329 | -0.081 | -19.8% | $0.325 | $0.363 | $0.320 | 900,000 | |
| $0.410 | -0.008 | -1.9% | $0.352 | $0.443 | $0.308 | 19,847,400 | |
| $0.418 | -0.001 | -0.2% | $0.410 | $0.426 | $0.361 | 71,100 | |
| $0.419 | -0.010 | -2.3% | $0.412 | $0.443 | $0.412 | 48,900 | |
| $0.429 | -0.011 | -2.5% | $0.442 | $0.461 | $0.411 | 68,700 | |
| $0.440 | -0.028 | -6.0% | $0.460 | $0.460 | $0.440 | 31,100 | |
| $0.468 | -0.007 | -1.5% | $0.461 | $0.506 | $0.460 | 14,500 | |
| $0.475 | +0.008 | +1.7% | $0.460 | $0.480 | $0.460 | 14,400 | |
| $0.467 | +0.007 | +1.5% | $0.499 | $0.499 | $0.463 | 18,400 | |
| $0.460 | +0.029 | +6.7% | $0.470 | $0.490 | $0.440 | 26,100 | |
| $0.431 | -0.050 | -10.4% | $0.467 | $0.500 | $0.431 | 36,000 | |
| $0.481 | +0.010 | +2.1% | $0.471 | $0.500 | $0.467 | 27,800 | |
| $0.471 | -0.001 | -0.2% | $0.470 | $0.500 | $0.468 | 9,200 | |
| $0.472 | -0.013 | -2.7% | $0.475 | $0.500 | $0.461 | 32,300 | |
| $0.485 | -0.017 | -3.4% | $0.550 | $0.560 | $0.480 | 62,600 | |
| $0.502 | -0.027 | -5.1% | $0.531 | $0.580 | $0.500 | 52,000 | |
| $0.529 | +0.003 | +0.6% | $0.569 | $0.579 | $0.509 | 56,900 | |
| $0.526 | -0.114 | -17.8% | $0.650 | $0.650 | $0.510 | 149,900 | |
| $0.640 | +0.029 | +4.7% | $0.650 | $0.650 | $0.586 | 45,200 | |
| $0.611 | -0.025 | -3.9% | $0.680 | $0.680 | $0.594 | 48,100 | |
| $0.636 | -0.024 | -3.6% | $0.730 | $0.730 | $0.623 | 27,400 | |
| $0.660 | -0.013 | -1.9% | $0.696 | $0.720 | $0.660 | 25,900 | |
| $0.673 | +0.035 | +5.5% | $0.620 | $0.740 | $0.620 | 82,000 | |
| $0.638 | -0.002 | -0.3% | $0.610 | $0.685 | $0.610 | 28,600 | |
| $0.640 | -0.006 | -0.9% | $0.622 | $0.720 | $0.620 | 53,300 | |
| $0.646 | +0.005 | +0.8% | $0.725 | $0.738 | $0.585 | 69,400 | |
| $0.641 | -0.049 | -7.1% | $0.719 | $0.744 | $0.640 | 17,300 | |
| $0.690 | -0.002 | -0.3% | $0.703 | $0.725 | $0.690 | 17,400 | |
| $0.692 | -0.033 | -4.6% | $0.720 | $0.725 | $0.692 | 4,900 | |
| $0.725 | +0.020 | +2.8% | $0.680 | $0.730 | $0.660 | 13,100 | |
| $0.705 | -0.017 | -2.4% | $0.755 | $0.755 | $0.625 | 44,300 | |
| $0.722 | -0.008 | -1.1% | $0.740 | $0.750 | $0.707 | 41,800 | |
| $0.730 | -0.003 | -0.4% | $0.750 | $0.750 | $0.725 | 11,900 | |
| $0.733 | -0.002 | -0.3% | $0.759 | $0.770 | $0.720 | 38,300 | |
| $0.735 | 0.000 | 0.0% | $0.757 | $0.764 | $0.720 | 20,300 | |
| $0.735 | -0.010 | -1.3% | $0.761 | $0.761 | $0.721 | 8,200 | |
| $0.745 | +0.008 | +1.1% | $0.770 | $0.770 | $0.720 | 29,700 |
- Ticker
- NASDAQ:ESLA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models
Latest deck · March 2026
Investor Presentation (March 2026)
Investor deck · 27 slides
Latest news
Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models
Nov 16, 2026
Closed $0.38 (-26.1%) on Nov 16, 2026
Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
Oct 26, 2026
Closed $0.919 (-6.7%) on Oct 26, 2026
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
Oct 15, 2026
Closed $0.43 (-19.6%) on Oct 16, 2026
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Oct 14, 2026
Closed $0.535 (+68.2%) on Oct 15, 2026
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
Jul 24, 2026
Closed $0.78 (+2.1%) on Jul 24, 2026
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
May 5, 2026
Closed $1.41 (-8.0%) on May 5, 2026
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
Mar 23, 2026
Closed $1.02 (-1.9%) on Mar 23, 2026
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Feb 9, 2026
Closed $1.43 (-1.7%) on Feb 9, 2026
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Feb 3, 2026
Closed $1.17 (+7.3%) on Feb 3, 2026
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
Jan 6, 2026
Closed $1.37 (+3.0%) on Jan 6, 2026
Estrella Immunopharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 14 in the last 12 months · 22 in all · newest Nov 16, 2026 · oldest 2024
- Decks
- 2 decks · latest March 2026
Where Estrella Immunopharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ESLA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ESLA | BOATS | United States | USD |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $14.01M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.31
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Estrella Immunopharma, Inc. · NASDAQ:ESLA | US$14.11M | US$14.01M | n/a | n/a | n/a | n/a | n/a | n/a | 1.31 |
| Context Therapeutics Inc. · NASDAQ:CNTX | US$14.70M | −US$19.50M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 0.99 |
| NewcelX Ltd. · NASDAQ:NCEL | US$14.67M | US$14.35M | n/a | n/a | n/a | 2.4× | n/a | 0.1× | 0.89 |
| Hepion Pharmaceuticals, Inc. · OTC:HEPA | US$14.63M | US$10.37M | n/a | n/a | n/a | n/a | n/a | n/a | -1.02 |
| Vectorite Biomedical, Inc. · TPEX:4170 | US$14.21M | US$9.16M | 4.9× | 4.9× | n/a | 0.9× | 156.6% | 0.0× | n/a |
| Citius Pharmaceuticals, Inc. · NASDAQ:CTXR | US$13.96M | −US$3.05M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 1.71 |
| TaiwanJ Pharmaceuticals Co., Ltd. · TPEX:6549 | US$13.69M | US$11.86M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| Actuate Therapeutics, Inc. · NASDAQ:ACTU | US$13.60M | US$11.50M | n/a | n/a | n/a | n/a | n/a | n/a | 1.75 |
| BeyondSpring, Inc. · NASDAQ:BYSI | US$13.57M | US$12.99M | 0.3× | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| Acumen Pharmaceuticals, Inc. · NASDAQ:ABOS | US$13.49M | −US$38.84M | n/a | n/a | n/a | 0.4× | n/a | 0.8× | 1.45 |
| Pharma Equity Group A/S Class A · OMXCOP:PEG | US$13.47M | US$15.05M | n/a | n/a | 52.7× | 3.6× | n/a | 0.4× | n/a |
| Median of the others | US$13.82M | US$10.94M | 2.6× | 4.9× | 52.7× | 0.9× | 156.6% | 0.0× | 1.31 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 12.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.29 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Cynthia Pussinen | Chairperson of the Board |
| Jiandong Xu | Chief Financial Officer |
| Cheng Liu | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Cynthia Pussinen | Chairperson of the Board |
| Dengyao Jia | Director |
| Fan Wu | Director |
| Hong Zhang | Director |
| Janelle Wu | Director |
| Marsha Roberts | Director |
| Pei Xu | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 | −26.8% |
| Q2 2026 | Aug 13, 2026 · After close | −0.3% |
| Q1 2026 | May 18, 2026 · Before open | +0.9% |
| Q4 2025 | Mar 18, 2026 · Before open | −2.7% |
| Q3 2025 | Nov 12, 2025 · After close | +4.8% |
| Q2 2025 | Aug 12, 2025 · Before open | 0.0% |
| Q1 2025 | May 14, 2025 · After close | −5.0% |
| Quarter to Dec 31, 2024 | Mar 25, 2025 · After close | −2.0% |
| Q3 2024 | Nov 14, 2024 | +6.0% |
| Q4 2022 | Mar 14, 2023 | −2.1% |
All 16 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2022 | Nov 14, 2022 | +0.3% |
| Q2 2022 | Aug 8, 2022 | 0.0% |
| Q1 2022 | May 16, 2022 | 0.0% |
| Q4 2021 | Mar 29, 2022 | 0.0% |
| Quarter to Sep 30, 2021 | Nov 10, 2021 | −0.4% |
| Quarter to Jun 30, 2021 | Jul 19, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2026) | Investor deck | 27 slides | March 2026 |
| Investor Presentation (April 2024) | Investor deck | 29 slides | Apr 10, 2024 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock and pre-funded warrants with concurrent private placement common warrants Closed: US$8M raised · US$1.58 a share · Warrants at US$1.39 for 60 months · Aegis Capital Corp. Dealers: Aegis Capital Corp. (lead) Use of proceeds: General corporate purposes and working capital | Jan 6, 2026 |
| Private placement of shares of common stock Announced: about US$3.35M · US$1.5 a share Use of proceeds: Complete Phase I of the STARLIGHT-1 trial of EB103 in adults with relapsed/refractory B-cell non-Hodgkin's lymphoma | Jun 3, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as TradeUP Acquisition Corp., a blank check company (SPAC). Priced at US$10.00 a unit on Jul 14, 2021.
- Price
- US$10.00 a unit
- Units offered
- 4,000,000 units
- Offering size
- US$40 million
- Underwriters' option
- Up to 600,000 more units
- Listing
- UPTDU on the Nasdaq Capital Market
- Underwriters
- Tiger Brokers, EF HUTTON, R. F. Lafferty & Co., Inc. · In the order on the cover
- Units delivered
- On or about Jul 19, 2021
Steps
| Step | When |
|---|---|
| Filed publicly | Feb 19, 2021 |
| Amended 9 times | Newest Jul 9, 2021 |
| Shares registered with an exchange | Jul 14, 2021 |
| Declared effective by the SEC | Jul 14, 2021 |
| Final prospectus, with the price | Jul 19, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 19, 2021 |
| CERT · Exchange's certificate of listing | Jul 15, 2021 |
| EFFECT · Notice that a registration is effective | Jul 14, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 14, 2021 |
| CORRESP · Letter to the SEC | Jul 13, 2021 |
| CORRESP · Letter to the SEC | Jul 13, 2021 |
| CORRESP · Letter to the SEC | Jul 9, 2021 |
| S-1/A · Registration statement, amended | Jul 9, 2021 |
| UPLOAD · Letter from the SEC | Jul 8, 2021 |
| S-1/A · Registration statement, amended | Jul 1, 2021 |
All 32 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jun 24, 2021 |
| CORRESP · Letter to the SEC | Jun 24, 2021 |
| CORRESP · Letter to the SEC | Jun 22, 2021 |
| CORRESP · Letter to the SEC | Jun 22, 2021 |
| CORRESP · Letter to the SEC | Jun 11, 2021 |
| S-1/A · Registration statement, amended | Jun 11, 2021 |
| UPLOAD · Letter from the SEC | Jun 2, 2021 |
| CORRESP · Letter to the SEC | May 28, 2021 |
| S-1/A · Registration statement, amended | May 28, 2021 |
| UPLOAD · Letter from the SEC | May 27, 2021 |
| S-1/A · Registration statement, amended | May 25, 2021 |
| S-1/A · Registration statement, amended | May 18, 2021 |
| CORRESP · Letter to the SEC | May 18, 2021 |
| UPLOAD · Letter from the SEC | May 17, 2021 |
| S-1/A · Registration statement, amended | May 7, 2021 |
| S-1/A · Registration statement, amended | Apr 12, 2021 |
| CORRESP · Letter to the SEC | Apr 9, 2021 |
| UPLOAD · Letter from the SEC | Apr 9, 2021 |
| S-1/A · Registration statement, amended | Mar 29, 2021 |
| CORRESP · Letter to the SEC | Mar 26, 2021 |
| UPLOAD · Letter from the SEC | Mar 18, 2021 |
| S-1 · Registration statement | Feb 19, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 19, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 10.2M | 4.11M | 10.5M | ||
| Operating income | -13.1M | -7.31M | -11.1M | -1.57M | -249.1K |
| Income before tax | -13.1M | -7.31M | -11.1M | -915.5K | -247.7K |
| Income tax | 838 | 1.63K | 80.6K | 0 | |
| Net income | -13.1M | -7.31M | -11.1M | -996.1K | -247.7K |
| Earnings per share, basic | -0.35 | -0.27 | -36.35 | -0.70 | -0.17 |
| Earnings per share, diluted | -0.35 | -0.27 | -36.35 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 1.38M | 4.17M | 2.48M | 40.8K | 478.9K |
| Receivables | 273.1K | ||||
| Current assets | 1.68M | 4.45M | 2.75M | 52.4K | 616.0K |
| Total assets | 3.18M | 4.45M | 3.03M | 9.72M | 45.8M |
| Current liabilities | 13.5M | 180.7K | 9.76M | 1.07M | 73.2K |
| Total liabilities | 13.5M | 180.7K | 9.77M | 2.65M | 1.62M |
| Shareholders' equity | -10.4M | 4.27M | -11.7M | -6.48M | -1.01M |
| Shares outstanding | 38.0M | 36.6M | 978.2K | 1.42M | 1.42M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | -1.79M | -16.1M | -1.34M | -1.04M | -316.2K |
| Cash from investing | 4.96M | -273.1K | 36.2M | -45.2M | |
| Cash from financing | 2.25M | 12.8M | -35.6M | 46.0M | |
| Change in cash | 467.4K | 1.69M | -1.61M | -438.1K | 478.9K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 29, 2026 | Management or board change | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 21, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jun 30, 2026 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | May 27, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | May 15, 2026 | Explanation request | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2026 | Annual report | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 17, 2026 | Annual report | SEC |
| 424B3 · Prospectus | Feb 13, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 26, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 22, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 21, 2026 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jan 16, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 13, 2026 | Current report | SEC |
| 8-K · Current report | Jan 6, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 6, 2026 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Dec 29, 2025 | Other filings | SEC |
| S-1 · Registration statement | Dec 22, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 4, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Oct 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 29, 2025 | Current report | SEC |
| 8-K · Current report | Sep 26, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Current report | SEC |
| 8-K · Current report | Jun 5, 2025 | Current report | SEC |
| 8-K · Current report | Jun 3, 2025 | Material contract | SEC |
| 8-K · Current report | May 29, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 2, 2025 | Current report | SEC |
| 10-KT · Transition report | Mar 25, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 21, 2025 | Current report | SEC |
| 8-K · Current report | Feb 19, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Dec 23, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 20, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 17, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Dec 17, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Dec 17, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 16, 2024 | Current report | SEC |
| S-3 · Registration statement | Dec 12, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Dec 9, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 6, 2024 | Material contract | SEC |
| 424B3 · Prospectus | Nov 27, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 26, 2024 | Current report | SEC |
| 8-K · Current report | Nov 25, 2024 | Current report | SEC |
| 424B3 · Prospectus | Nov 18, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K/A · Current report, amended | Nov 7, 2024 | Material contract | SEC |
| 8-K · Current report | Nov 7, 2024 | Management or board change | SEC |
| 10-K/A · Annual report, amended | Oct 28, 2024 | Annual report | SEC |
| 424B3 · Prospectus | Oct 2, 2024 | Offer document | SEC |
| 10-K · Annual report | Sep 26, 2024 | Annual report | SEC |
| 3 · Initial statement of ownership | Aug 23, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Aug 21, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 20, 2024 | Management or board change | SEC |
| 424B3 · Prospectus | Aug 6, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 5, 2024 | Current report | SEC |
| 424B3 · Prospectus | Jul 2, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 1, 2024 | Current report | SEC |
| 424B3 · Prospectus | May 15, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2024 | Material contract | SEC |
| 8-K · Current report | Apr 10, 2024 | Current report | SEC |
| 424B3 · Prospectus | Mar 8, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 8, 2024 | Current report | SEC |
| 424B3 · Prospectus | Mar 7, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 6, 2024 | Material contract | SEC |
| 424B3 · Prospectus | Feb 15, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Feb 14, 2024 | Quarterly report | SEC |
| 424B3 · Prospectus | Feb 12, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 2, 2024 | Current report | SEC |
| 8-K · Current report | Jan 30, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 29, 2023 | Other filings | SEC |
| 424B3 · Prospectus | Dec 28, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 27, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 15, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 15, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Nov 21, 2023 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 20, 2023 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Nov 14, 2023 | Explanation request | SEC |
| 8-K/A · Current report, amended | Nov 14, 2023 | Current report | SEC |
| CORRESP · Letter to the SEC | Nov 13, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Nov 13, 2023 | Offer document | SEC |
| SC 13D · Big-stake notice | Oct 27, 2023 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Oct 23, 2023 | Other filings | SEC |
| S-1 · Registration statement | Oct 10, 2023 | Offer document | SEC |
| 3 · Initial statement of ownership | Oct 10, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 10, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 5, 2023 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Oct 5, 2023 | Insider trade | SEC |
| 25-NSE | Oct 5, 2023 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 425 | Sep 20, 2023 | Other filings | SEC |
| 8-K · Current report | Sep 20, 2023 | Material contract | SEC |
| 425 | Sep 18, 2023 | Other filings | SEC |
| 8-K · Current report | Sep 18, 2023 | Material contract | SEC |
| 425 | Aug 18, 2023 | Other filings | SEC |
| 8-K · Current report | Aug 18, 2023 | Material contract | SEC |
| 10-Q · Quarterly report | Jul 31, 2023 | Quarterly report | SEC |
| 425 | Jul 31, 2023 | Other filings | SEC |
| 8-K · Current report | Jul 31, 2023 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jul 26, 2023 | Meeting notice | SEC |
| 425 | Jul 26, 2023 | Other filings | SEC |
| 8-K · Current report | Jul 26, 2023 | Material contract | SEC |
| SEC STAFF LETTER | Jul 25, 2023 | Other filings | SEC |
| 8-K · Current report | Jul 21, 2023 | Material contract | SEC |
| 425 | Jul 19, 2023 | Other filings | SEC |
| 8-K · Current report | Jul 19, 2023 | Material contract | SEC |
| 8-K · Current report | Jul 19, 2023 | Material contract | SEC |
| DEFA14A · Additional proxy material | Jul 12, 2023 | Meeting notice | SEC |
| 8-K · Current report | Jul 12, 2023 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 12, 2023 | Other filings | SEC |
| 424B3 · Prospectus | Jul 11, 2023 | Offer document | SEC |
| S-4/A · Registration statement, amended | Jul 7, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 6, 2023 | Other filings | SEC |
| S-4/A · Registration statement, amended | Jul 6, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 30, 2023 | Other filings | SEC |
| S-4/A · Registration statement, amended | Jun 30, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 26, 2023 | Other filings | SEC |
| 8-K · Current report | Jun 23, 2023 | Current report | SEC |
| 425 | Jun 20, 2023 | Other filings | SEC |
| 8-K · Current report | Jun 20, 2023 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Jun 16, 2023 | Other filings | SEC |
| DEF 14A · Proxy statement | Jun 16, 2023 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Jun 15, 2023 | Other filings | SEC |
| S-4/A · Registration statement, amended | Jun 15, 2023 | Offer document | SEC |
| 8-K · Current report | Jun 9, 2023 | Material contract | SEC |
| PRER14A | Jun 2, 2023 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | May 25, 2023 | Meeting notice | SEC |
| 425 | May 19, 2023 | Other filings | SEC |
| 8-K · Current report | May 19, 2023 | Material contract | SEC |
| 10-Q · Quarterly report | May 17, 2023 | Quarterly report | SEC |
| UPLOAD · Letter from the SEC | May 17, 2023 | Other filings | SEC |
| NT 10-Q · Late filing notice | May 15, 2023 | Explanation request | SEC |
| SEC STAFF LETTER | May 12, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 1, 2023 | Other filings | SEC |
| S-4/A · Registration statement, amended | May 1, 2023 | Offer document | SEC |
| 425 | Apr 26, 2023 | Other filings | SEC |
| 8-K · Current report | Apr 26, 2023 | Material contract | SEC |
| 425 | Apr 24, 2023 | Other filings | SEC |
| 8-K · Current report | Apr 24, 2023 | Material contract | SEC |
| 8-K · Current report | Apr 21, 2023 | Current report | SEC |
| 425 | Apr 13, 2023 | Other filings | SEC |
| 8-K · Current report | Apr 13, 2023 | Material contract | SEC |
| 8-K · Current report | Apr 5, 2023 | Current report | SEC |
| 425 | Mar 17, 2023 | Other filings | SEC |
| 8-K · Current report | Mar 17, 2023 | Material contract | SEC |
| 10-K · Annual report | Mar 14, 2023 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 10, 2023 | Big-stake notice | SEC |
| 425 | Mar 8, 2023 | Other filings | SEC |
| 8-K · Current report | Mar 3, 2023 | Material contract | SEC |
| SEC STAFF LETTER | Feb 22, 2023 | Other filings | SEC |
| 425 | Feb 21, 2023 | Other filings | SEC |
| 8-K · Current report | Feb 21, 2023 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Feb 17, 2023 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| S-4/A · Registration statement, amended | Feb 2, 2023 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 31, 2023 | Big-stake notice | SEC |
| 425 | Jan 24, 2023 | Other filings | SEC |
| 8-K · Current report | Jan 24, 2023 | Material contract | SEC |
| 3 · Initial statement of ownership | Jan 9, 2023 | Insider trade | SEC |
| 8-K · Current report | Jan 5, 2023 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Dec 29, 2022 | Other filings | SEC |
| 8-K · Current report | Dec 29, 2022 | Meeting outcome | SEC |
| S-4/A · Registration statement, amended | Dec 16, 2022 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 16, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 7, 2022 | Other filings | SEC |
| DEF 14A · Proxy statement | Dec 6, 2022 | Meeting notice | SEC |
| PRER14A | Dec 2, 2022 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Nov 25, 2022 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Nov 14, 2022 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 14, 2022 | Quarterly report | SEC |
| S-4 · Registration statement | Oct 17, 2022 | Offer document | SEC |
| 8-K · Current report | Oct 11, 2022 | Current report | SEC |
This page holds 200 of 260 filings. Open Filings
Cap table
Built by 6ix from Estrella Immunopharma, Inc.’s releases · as of Nov 11, 2026
- Common shares
- 43,970,085
- Fully diluted
- 43,970,085
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 43,970,085 | Nov 11, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.39 · expire about Jan 2031 |
Share count over time
| Count | Shares |
|---|---|
| Nov 11, 2026 | 43,970,085 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Pei Xu Other companies: Zhongchao Inc. (Chief Financial Officer, Director · Since at least Mar 18, 2026) | Director · Since at least Sep 29, 2023 |
| Cheng Liu | Chief Scientific Officer · Since at least Sep 29, 2023 |
| Cynthia Pussinen | Chairperson of the Board · Since Oct 25, 2026 |
| Dengyao Jia | Director · Since at least Nov 5, 2026 |
| Fan Wu | Director · Since at least Sep 29, 2023 |
| Hong Zhang | Director · Since at least Nov 5, 2026 |
| Janelle Wu | Director · Since at least Nov 5, 2026 |
| Jiandong Xu | Chief Financial Officer · Since at least Aug 25, 2026 |
| Marsha Roberts | Director · Since at least Sep 29, 2023 |
Log in to ask 6ix AI your own questions about Estrella Immunopharma, Inc.